SCHEMBL5455524

SCHEMBL5455524

CCOc1ccc(NC(=S)NC(=O)/C=C/c2ccccc2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.79
KMT2A Q03164 8/20 0.78
MEN1 O00255 4/20 0.72
LMNA P02545 3/20 0.72
TDP1 Q9NUW8 2/20 0.72
POLB P06746 2/20 0.72
BLM P54132 1/20 0.72
RAB9A P51151 1/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
MAPT P10636 4/20 0.63
ALDH1A1 P00352 2/20 0.63
KDM4E B2RXH2 1/20 0.63
HPGD P15428 1/20 0.63
HTT P42858 1/20 0.63
MAOA P21397 1/20 0.57
MAOB P27338 1/20 0.57
MMP1 P03956 1/20 0.57
MMP2 P08253 1/20 0.57
MMP9 P14780 1/20 0.57
GAA P10253 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5455527 1.00 EGFR (0.79) EGFRKMT2AMEN1LMNATDP1
SCHEMBL4971304 0.84 KMT2A (0.81) EGFRKMT2AMEN1LMNATDP1
SCHEMBL4971301 0.84 KMT2A (0.81) EGFRKMT2AMEN1LMNATDP1
SCHEMBL25222060 0.83 EGFR (0.90) EGFRKMT2AMEN1LMNAPOLB
SCHEMBL5446943 0.82 KMT2A (0.74) KMT2AMEN1LMNATDP1POLB
SCHEMBL5446938 0.82 KMT2A (0.74) KMT2AMEN1LMNATDP1POLB
SCHEMBL7814633 0.81 RAB9A (0.81) KMT2AMEN1LMNATDP1POLB
SCHEMBL7814630 0.81 RAB9A (0.81) KMT2AMEN1LMNATDP1POLB
SCHEMBL14096628 0.80 MAPT (0.78) KMT2AMEN1LMNATDP1POLB
SCHEMBL14095995 0.80 RAB9A (0.67) KMT2AMEN1LMNATDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101129295-B There is the binary initiator system of good storage stability and especially suitable for acidic system HERAEUS KULZER GMBH (DE) 2016-02-10 CN disclosed
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv ACHILLION PHARMACEUTICALS, INC. (US) 2008-08-28 US disclosed
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv ACHILLION PHARMACEUTICALS, INC. (US) 2008-08-28 US disclosed
CN-101129295-A 2-component initiator system (amine free) with storage stability and especially suitable for acidic systems HERAEUS KULZER GMBH (DE) 2008-02-27 CN disclosed
US-20070040151-A1 Two-component initiator system (amine-free) with very good storage stability and particular suitability for acid systems HERAEUS KULZER GMBH (DE) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv RNASE1, SARS1, EIF2AK2 EGFR 4435/4885KMT2A 4579/4885MEN1 4577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.